High-density EEG study in patients with schizophrenia treated with cariprazine
International Journal of Neuropsychopharmacology · 2026
DOI: 10.1093/ijnp/pyag008 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Neuropsychopharmacology, 2026. Verfasst von Pál Czobor und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary. Hauptthemen laut MEDLINE: Schizophrenia, Piperazines, Antipsychotic Agents, Electroencephalography. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gedeon Richter, Plc.
Abstract (Originalsprache)
Background
Schizophrenia is marked by persistent negative and cognitive symptoms that remain difficult to treat. Cariprazine, a dopamine D3/D2 partial agonist, has demonstrated efficacy in these domains, making it essential to clarify its neurophysiological mechanisms both for future drug discovery and clinical application. Resting-state EEG spectral analysis provides a non-invasive and translational tool for monitoring neurophysiological changes related to treatment. However, data on EEG spectral effects in human patients treated with cariprazine are currently lacking.
Methods
In this open-label investigation, 27 patients with schizophrenia underwent high-density resting-state EEG before and during cariprazine treatment. Power spectral analyses were conducted across frequency bands and cortical regions, with ROI analyses targeting gamma-activity in DLPFC, IFG, and TPJ. Symptom changes were measured using the Positive and Negative Syndrome Scale.
Results
Cariprazine treatment led to symptom improvement, particularly in negative and general domains. EEG analyses showed increased spectral power, most prominently in the theta and alpha bands, mirroring findings from the only available in vivo preclinical study, which also reported theta and alpha elevations in rodents. Symptom reduction was specifically associated with increased theta and decreased delta power. Moreover, baseline gamma-activity—especially in the IFG and DLPFC—predicted treatment response, with Receiver Operating Characteristic analyses yielding AUC values of 0.72-0.92 and cross-validated classification accuracies exceeding 70%.
Conclusions
Together, our results demonstrate that resting-state EEG spectral measures reflect neurophysiological correlates of cariprazine response. Furthermore, the findings reinforce the cross-species translatability of spectral measures and support EEG biomarkers as promising translational tools for predicting and monitoring treatment outcomes in schizophrenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary.
ORCID-Profile: Pál Czobor
Förderung
- Gedeon Richter, Plc
Zitieren
APA
Czobor, P., Kakuszi, B., Fullajtár, M., & Bitter, I. (2026). High-density EEG study in patients with schizophrenia treated with cariprazine. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyag008
Vancouver
Czobor P, Kakuszi B, Fullajtár M, Bitter I. High-density EEG study in patients with schizophrenia treated with cariprazine. International Journal of Neuropsychopharmacology. 2026. doi:10.1093/ijnp/pyag008
BibTeX
@article{Czobor2026,
author = {Czobor, Pál and Kakuszi, Brigitta and Fullajtár, Máté and Bitter, István},
title = {High-density EEG study in patients with schizophrenia treated with cariprazine},
journal = {International Journal of Neuropsychopharmacology},
year = {2026},
doi = {10.1093/ijnp/pyag008}
}
EUVIMED